

or other Axis-I disorders according to DSM-IV. No structured methods were used to assess psychiatric symptoms in the controls, which included hospital staff, their families and medical students.

The study was described to subjects and written informed consent was obtained from each. This study was approved by the ethics committee at Fujita Health University and Nagoya University School of Medicine.

SNP selection and linkage disequilibrium (LD) evaluation

We first consulted the HapMap database (release no. 23.a. phase2, March 2008, <http://www.hapmap.org>, population: Japanese Tokyo: minor allele frequencies (MAFs) of more than 0.05) and included three SNPs (rs6449693, rs878567 and rs1423691) covering HTR1A (5'-flanking regions including ~1 kb from the initial exon and ~2 kb downstream (3') from the last exon: HapMap database contig number chr5: 63287418.63291774) (Figure 1). One tagging SNP was then selected with the criteria of an r^2 -threshold >0.8 in 'pairwise-tagging-only' mode using the 'Tagger' program (Paul de Bakker, <http://www.broadinstitute.org/tagger-0>) of the HAPLOVIEW software.⁹

HTR1A has also been reported to have one biologically functional SNP (C-1019G: rs6295).^{4,10,11} rs6295 (C-1019G) in the promoter region regulates HTR1A transcription.^{4,5} The C allele is a part of a 26 palindrome that connects transcription factors (Deaf-1, Hes1 and Hes5) by NUDR (nuclear deformed epidermal auto regulatory factor), whereas the G allele turns off repression by NUDR.^{4,5} This would lead to elevated levels of 5-HT1A receptor in the presynaptic raphe nucleus in GG genotypes, compared with the CC genotype.^{4,5} As no information about rs6295 was shown in the HapMap database, we included this SNP. These two SNPs were then used for the following association analysis.

SNP genotyping

We used TaqMan assays (Applied Biosystems, Foster City, CA, USA) for both SNPs. Detailed information, including primer sequences and reaction conditions, is available on request.

Statistical analysis

Case-control association study based on LD. Genotype deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated by χ^2 test (SAS/Genetics, release 8.2, SAS Japan, Tokyo, Japan).

Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the χ^2 test (SAS/Genetics, release 8.2, SAS Japan), and haplotype-wise association analysis was conducted with a likelihood ratio test using the COCAPHASE2.403 program.¹² Power calculation was performed using the Genetic Power Calculator.¹³ Bonferroni's correction was used to control inflation of the type I error rate. The significance level for all statistical tests was 0.05.

Meta-analysis. To identify studies eligible for the meta-analysis, we searched PubMed citations through March 2009 using the terms 'HTR1A,' 'serotonin 1A receptor gene,' 'major depressive disorder' and 'MDD' as key words.

As criteria selected for eligible studies, we referred to the study by López-León et al.³ In summary, eligible studies had to meet all of the following criteria: (1) be published in peer-reviewed journal, (2) have cases not selected by questionnaires assessing symptoms of depression, (3) contain independent data, (4) have distribution of genotypes in the control population that was in the HWE, (5) be case-control association studies investigating one or more of the three polymorphisms, (6) have MDD patients diagnosed according to ICD and DSM and (7) use healthy individuals as controls in case-control studies.

Cochran's χ^2 -based Q-statistic test was applied to assess between-study heterogeneity. The significance of the pooled odds ratio (OR) was determined using a Z-test. Overall, ORs and their 95% confidence intervals (95% CIs) were estimated under both the Mantel-Haenszel¹⁴ fixed-effects and DerSimonian-Laird¹⁵ random-effects models. The random-effects model is more conservative than is the fixed-effects model and produces a wider CI. When there is no evidence of heterogeneity, the random-effects model will yield similar results to the fixed-effects model. Therefore, if it is confirmed that there was no heterogeneity, we could calculate pooled ORs and P-values according to the Mantel-Haenszel fixed-effects model. If there was evidence of heterogeneity, we could calculate pooled ORs and P-values according to the DerSimonian and Laird random-effects model. Publication bias was evaluated using a funnel plot asymmetry with Egger's test. The statistical significance was set at 0.05. All data were analyzed using Comprehensive Meta Analysis (Version 2.0). More detailed information about the meta-analysis method is given in our previous papers. Bonferroni's correction was used to control inflation of the type I error rate. The significance level for all statistical tests was 0.05.

RESULTS

The LD from rs6449693, rs878567 and rs1423691 was tight, according to the HapMap database samples ($r^2=1.00$). However, the LD structure of rs6295 (functional SNP) and rs878567 (tagging SNP) in our control samples was not tight ($r^2=0.160$). Genotype frequencies of all SNPs were in the HWE. We found an association between rs878567 and Japanese MDD patients in the allele-wise analysis ($P=0.0448$), but this significance did not remain after Bonferroni's correction ($P=0.0896$). We also did not detect any association between HTR1A and MDD in the allele/genotype-wise (Table 1) or in the haplotype-wise analysis ($P=0.126$).

In the meta-analysis, seven population-based association studies, including this study, met our criteria for rs6295^{4,6,16-19} (Table 2). We found significant heterogeneity among ORs ($Q=16.2$, $df=6$, $P(Q)=0.0119$). The pooled OR derived from all studies comprising




Figure 1 Forest plots of odds ratio (OR) with 95% confidence interval (95% CI) for rs6295. Results of all pooled studies are shown. We found significant heterogeneity among ORs ($Q=16.2$, $df=6$, $P(Q)=0.0119$). Therefore, we could calculate pooled ORs and P-values according to the DerSimonian and Laird random-effects model.

Table 1 Tagging SNPs and association analysis of *HTR1A*

| SNP | Phenotype ^a | MAF | N | Genotype distribution ^b | | | HWE ^c | P-value ^d | | Corrected P-value |
|----------|------------------------|-------|-----|------------------------------------|-----|-----|------------------|----------------------|---------------|-------------------|
| | | | | M/M | M/m | m/m | | Genotype | Allele | |
| rs6295 | Controls | 0.235 | 804 | 474 | 282 | 48 | 0.484 | | | |
| | MDD | 0.246 | 331 | 190 | 119 | 22 | 0.567 | 0.851 | 0.571 | |
| rs878567 | Controls | 0.115 | 804 | 634 | 155 | 15 | 0.131 | | | |
| | MDD | 0.145 | 331 | 243 | 80 | 8 | 0.645 | 0.138 | 0.0448 | 0.0896 |

Abbreviations: HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; MDD, major depressive disorder; SNP, single-nucleotide polymorphism.

^aMDD.

^bM: major allele, m: minor allele.

^cHWE.

^dBold numbers represent significant P-value.

Table 2 Studies included in meta-analysis for rs6295

| Authors | Year | Ethnicity | Diagnostic system | N ^{a,b} | | C ^{a,c} | | G ^{a,d} | | OR ^e | CI ^f | P(Z) ^g |
|---------|------|---------------------------------|-------------------|------------------|------|------------------|------|------------------|------|-----------------|-----------------|-------------------|
| | | | | MDD | CON | MDD | CON | MDD | CON | | | |
| Kishi | | Asian | DSM-IV | 331 | 804 | 499 | 1230 | 163 | 378 | 0.941 | 0.761–1.16 | 0.571 |
| Wu | 2008 | Asian | DSM-IV | 400 | 400 | 558 | 615 | 242 | 185 | 0.694 | 0.555–0.867 | 0.00131 |
| Neff | 2008 | Caucasian | DSM-IV-TR | 344 | 336 | 338 | 360 | 350 | 312 | 0.837 | 0.676–1.04 | 0.101 |
| Koks | 2006 | Caucasian | DSM-IV | 177 | 160 | 141 | 132 | 163 | 176 | 1.15 | 0.838–1.59 | 0.381 |
| Parsey | 2006 | Caucasian | DSM-IV | 28 | 42 | 24 | 49 | 32 | 35 | 0.536 | 0.270–1.06 | 0.0738 |
| Lemonde | 2003 | Caucasian | DSM-IV | 129 | 134 | 123 | 168 | 135 | 100 | 0.542 | 0.383–0.768 | 0.000565 |
| Arias | 2002 | Caucasian | DSM-III-R | 249 | 170 | 232 | 158 | 266 | 182 | 1.00 | 0.762–1.32 | 0.974 |
| | | Pooled all studies ^h | | 1658 | 2046 | 1915 | 2712 | 1351 | 1368 | 0.822 | 0.685–0.984 | 0.0327 |

Abbreviations: CI, confidence interval; CON, controls; MDD, major depressive disorder; OR, odds ratio.

^aMDD, CON.

^bN: number of samples.

^cC: allele C.

^dG: allele G.

^eOR.

^fCI.

^gP(Z): Z-test was used to detect the significance of the overall OR. Bold numbers represent significant P-value.

^hWe found significant heterogeneity among ORs ($Q=16.2$, $df=6$, $I^2=0.0119$). Therefore, we could calculate pooled ORs and P-values according to the DerSimonian and Laird random-effects model.

1658 patients and 2046 control subjects indicated a significant association (random model: OR=0.821, 95% CI=0.695–0.984, $P(Z)=0.0327$) (Table 2) (Figure 1). Next, to limit ethnic heterogeneity, we included an explorative analysis with either Caucasian or Asian samples. We did not observe significant heterogeneity among ORs in the Asian population ($Q=4.30$, $df=1$, $P(Q)=0.133$). However, we found significant heterogeneity among ORs in the Caucasian population ($Q=13.1$, $df=4$, $P(Q)=0.0108$). We detected a significant association between rs6295 and MDD in the Asian population (fixed model: pooled OR=0.815, 95% CI=0.699–0.950, $P(Z)=0.00878$) (Figure 2). Moreover, these associations were still significant after correction for multiple testing (fixed model: $P(Z)=0.0176$) (Figure 2). In addition, rs6295 was not associated with MDD in the Caucasian population (random model: OR=0.819, 95% CI=0.629–1.066, $P(Z)=0.138$) (Figure 1). No publication bias was found ($t=0.685$, $P=0.524$).


DISCUSSION

We detected an association between rs6295 and MDD in the meta-analysis. However, because significant heterogeneity among ORs was found ($P=0.0119$), we carried out an explorative analysis with either Caucasian or Asian samples. We detected a significant association between rs6295 and MDD in the Asian population, but did not

observe significant heterogeneity among ORs ($P=0.133$). On the other hand, we observed significant heterogeneity among ORs in the Caucasian population ($P=0.0108$). The heterogeneity may result from (1) different ancestries (Asian population versus Caucasian population), (2) incomplete genotyping rates or genotyping error rates in different studies. Although the studies by Arias *et al.*¹⁶ and Koks *et al.*¹⁸ reported that the major allele was 'G', other studies showed that the major allele was 'C'. We contacted the corresponding authors with regard to the genotype data in these studies. They and Kato *et al.*²⁰ informed us that there were no genotyping errors. (3) The overall sample size included in the meta-analysis was relatively small (1658 patients and 2046 control subjects).²¹ To overcome these limitations, a replication study using larger samples or samples of other populations will be required for conclusive results.

In our case-control study, no association was found. Although the Japanese and Chinese populations are both classified as Asian populations, rs6295 was associated with Chinese MDD patients,^{6,7} but not with Japanese MDD patients. Several reasons may explain these inconsistent findings, including allelic heterogeneity, true variation in disease association between populations, modifying genetic and/or environmental factors and statistically underpowered small sample sizes. In rs6295, the MAFs in MDD in the Japanese population (0.246)

Asian population



Caucasian population




Figure 2 Forest plots of odds ratio (OR) with 95% confidence interval (95% CI) for rs6295. Results of subgroup analysis are shown. We did not observe significant heterogeneity among ORs in the Asian population ($Q=4.30$, $df=1$, $P(Q)=0.133$). Therefore, we could calculate pooled ORs and P -values according to the Mantel-Haenszel fixed-effects model. However, we found significant heterogeneity among ORs in the Caucasian population ($Q=13.1$, $df=4$, $P(Q)=0.0108$). Therefore, we could calculate pooled ORs and P -values according to the DerSimonian and Laird random-effects model.

seem to be smaller compared with those in the Chinese population (0.303).⁶ The MAFs in Japanese controls were similar to those in Chinese controls (0.231).⁶ Although classified in the same Asian population, the susceptibility genes for MDD might be not common. Recent evidence supports this hypothesis. The serotonin 2A gene was associated with MDD in the Korean population,²² but not in Japanese population.²³ rs6295 (C-1019G) in the promoter region regulates *HTR1A* transcription.^{4,5} The C allele is part of a 26 palindrome that connects transcription factors (Deaf-1, Hes1 and Hes5) by NUDR, whereas the G allele turns off repression by NUDR.^{4,5} This would lead to elevated levels of 5-HT_{1A} receptor in the presynaptic raphe nucleus in GG genotypes compared with the CC genotype.^{4,5} In several studies, these variants were associated with responses including the antidepressant response in MDD.^{24–29} Recently, Kato and Serretti³⁰ reported a meta-analysis between rs6295 and antidepressant efficacy in MDD. The authors showed that the pooled OR derived from six studies comprising 893 patients was not significant.³⁰ The pooled OR of studies in Caucasian populations only was also not significant.³⁰ However, the pooled OR of the studies in Asian studies only did show a significant association.³⁰ Therefore, the authors suggested that the rs6295 genotype may be a predictor of antidepressant treatment response in MDD in the Asian population.³⁰

A few points of caution should be mentioned with respect to our results. First, our sample sizes were small. In the power analysis, we obtained power of more than 80% for the detection of association when we set the genotype relative risk at 1.33–1.51 in MDD for *HTR1A*, under a multiplicative model of inheritance. As our samples were small, type II errors are possible in the results of these statistical association analyses. Second, we did not perform a mutation scan of *HTR1A*. As we consider it to be difficult to evaluate the association of such extremely rare variants from the viewpoint of statistical power, a replication study using a larger sample is required for conclusive

results. Finally, our subjects did not undergo structured interviews. MDD patients who are not diagnosed by structured interview may develop bipolar disorder in the future.³¹ However, in this study, patients were carefully diagnosed according to the DSM-IV criteria with the consensus of at least two experienced psychiatrists on the basis of a review of medical records. In addition, when we found a misdiagnosis in a patient, we promptly excluded the misdiagnosed case in consideration of the precision of our sample. Detailed information on our samples was provided in previous papers.^{32–35}


In conclusion, our results suggest that *HTR1A* may not have a role in the pathophysiology of Japanese MDD patients. On the other hand, according to the meta-analysis, *HTR1A* was associated with MDD patients, especially in the Asian population. As our sample and the overall sample size included in the meta-analysis were relatively small, statistical errors are possible in the results of these statistical association analyses. To overcome these limitations, a replication study using a larger sample may be required for conclusive results.

ACKNOWLEDGEMENTS

We thank Ms M Miyata and Ms S Ishihara for their technical support. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labor and Welfare, and the Japan Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation).

- 1 Kato, T. Molecular genetics of bipolar disorder and depression. *Psychiatry Clin Neurosci* **61**, 3–19 (2007).
- 2 Levinson, D. F. The genetics of depression: a review. *Biol Psychiatry* **60**, 84–92 (2006).
- 3 López-León, S., Janssens, A. C., Gonzalez-Zuloeta Ladd, A. M., Del-Favero, J., Claes, S. J., Oostra, B. A. et al. Meta-analyses of genetic studies on major depressive disorder. *Mol Psychiatry* **13**, 772–785 (2008).

- 4 Lemonde, S., Turecki, G., Bakish, D., Du, L., Hrdina, P. D., Bown, C. D. et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. *J Neurosci* **23**, 8788–8799 (2003).
- 5 Le Francois, B., Czesak, M., Steubl, D., Albert, P. R. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. *Neuropharmacology* **55**, 977–985 (2008).
- 6 Wu, Y., Xu, Y., Sun, Y., Wang, Y. F., Li, X., Lang, X. E. et al. Association between the serotonin 1A receptor C(-1019)G polymorphism and major depressive disorder in the northern Han ethnic group in China. *Chin Med J* **121**, 874–876 (2008).
- 7 Zhang, K., Xu, Q., Xu, Y., Yang, H., Luo, J., Sun, Y. et al. The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. *J Affect Disord* **114**, 224–231 (2009).
- 8 Neale, B. M. & Sham, P. C. The future of association studies: gene-based analysis and replication. *Am J Hum Genet* **75**, 353–362 (2004).
- 9 Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics (Oxford, England)* **21**, 263–265 (2005).
- 10 Albert, P. R., Lembo, P., Storing, J. M., Charest, A. & Saucier, C. The 5-HT1A receptor: signaling, desensitization, and gene transcription. *Neuropsychopharmacology* **14**, 19–25 (1996).
- 11 Albert, P. R. & Lemonde, S. 5-HT1A receptors, gene repression, and depression: guilt by association. *Neuroscientist* **10**, 575–593 (2004).
- 12 Dudbridge, F. Pedigree disequilibrium tests for multilocus haplotypes. *Genet Epidemiol* **25**, 115–121 (2003).
- 13 Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics (Oxford, England)* **19**, 149–150 (2003).
- 14 Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* **22**, 719–748 (1959).
- 15 DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials* **7**, 177–188 (1986).
- 16 Arias, B., Arranz, M. J., Gasto, C., Catalan, R., Pintor, L., Gutierrez, B. et al. Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. *Mol Psychiatry* **7**, 930–932 (2002).
- 17 Neff, C. D., Abkevich, V., Packer, J. C., Chen, Y., Potter, J., Riley, R. et al. Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. *Mol Psychiatry* **14**, 621–630 (2008).
- 18 Koks, S., Nikopensius, T., Koido, K., Maron, E., Altmäe, S., Heinaste, E. et al. Analysis of SNP profiles in patients with major depressive disorder. *Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* **9**, 167–174 (2006).
- 19 Parsey, R. V., Oquendo, M. A., Ogden, R. T., Olivet, D. M., Simpson, N., Huang, Y. Y. et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. *Biol Psychiatry* **59**, 106–113 (2006).
- 20 Kato, M., Fukuda, T., Wakeno, M., Okugawa, G., Takekita, Y., Watanabe, S. et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. *Am J Med Genet B Neuropsychiatr Genet* **150B**, 115–123 (2009).
- 21 Shi, J., Badner, J. A., Gershon, E. S. & Liu, C. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. *Schizophrenia Res* **98**, 89–97 (2008).
- 22 Choi, M. J., Lee, H. J., Lee, H. J., Ham, B. J., Cha, J. H., Ryu, S. H. et al. Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene. *Neuropsychobiology* **49**, 38–41 (2004).
- 23 Kishi, T., Kitajima, T., Tsunoka, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y. et al. Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. *Neurosci Res* **64**, 231–234 (2009).
- 24 Serretti, A., Artioli, P., Lorenzi, C., Pirovano, A., Tubazio, V. & Zanardi, R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. *Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* **7**, 453–460 (2004).
- 25 Lemonde, S., Du, L., Bakish, D., Hrdina, P. & Albert, P. R. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. *Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* **7**, 501–506 (2004).
- 26 Arias, B., Catalan, R., Gasto, C., Gutierrez, B. & Fananas, L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. *J Psychopharmacol (Oxford, England)* **19**, 166–172 (2005).
- 27 Parsey, R. V., Olivet, D. M., Oquendo, M. A., Huang, Y. Y., Ogden, R. T. & Mann, J. J. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. *Neuropsychopharmacology* **31**, 1745–1749 (2006).
- 28 Hong, C. J., Chen, T. J., Yu, Y. W. & Tsai, S. J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. *Pharmacogenomics* **7**, 27–33 (2006).
- 29 Yu, Y. W., Tsai, S. J., Liou, Y. J., Hong, C. J. & Chen, T. J. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. *Eur Neuropsychopharmacol* **16**, 498–503 (2006).
- 30 Kato, M. & Serretti, A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. *Mol Psychiatry* (2008) (in press).
- 31 Bowden, C. L. Strategies to reduce misdiagnosis of bipolar depression. *Psychiatr Serv (Washington, DC)* **52**, 51–55 (2001).
- 32 Kishi, T., Ikeda, M., Kitajima, T., Suzuki, T., Yamanouchi, Y., Kinoshita, Y. et al. No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. *Am J Med Genet B Neuropsychiatr Genet* **147B**, 531–534 (2008).
- 33 Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K. et al. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. *Eur Arch Psychiatry Clin Neurosci* **259**, 293–297 (2009).
- 34 Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K. et al. Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. *Neurosci Res* **62**, 211–215 (2008).
- 35 Kishi, T., Kitajima, T., Tsunoka, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y. et al. Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. *Neurosci Res* **64**, 231–234 (2009).



Prepulse inhibition of the startle response with chronic schizophrenia: A replication study

Masatsugu Moriwaki^{a,b,1}, Taro Kishi^{a,c,1,*}, Hidetoshi Takahashi^{c,d}, Ryota Hashimoto^{c,d,e},
Kunihiro Kawashima^{a,c,f}, Tomo Okochi^{a,c}, Tsuyoshi Kitajima^{a,c}, Osamu Furukawa^b,
Kiyoshi Fujita^b, Masatoshi Takeda^{d,e}, Nakao Iwata^{a,c}

^a Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan

^b Okeazama Hospital, Toyoake, Aichi 470-1168, Japan

^c Japan Science and Technology Agency, CREST, Kawaguchi, Saitama, Japan

^d Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

^e The Osaka-Hamamatsu Joint Research Center for Child Mental Development, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan

^f Jindai Hospital, Toyota, Aichi 470-0361, Japan

ARTICLE INFO

Article history:

Received 8 June 2009

Received in revised form 22 July 2009

Accepted 24 July 2009

Available online 4 August 2009

Keywords:

Prepulse inhibition
Acoustic startle reflex
Habituation
Schizophrenia

ABSTRACT

Prepulse inhibition (PPI) deficit, the acoustic startle reflex (ASR) and habituation (HAB) impairment are considered to be endophenotypes for schizophrenia. The recent two studies have reported that a PPI deficit was detected in Japanese schizophrenic patients. We replicated that study using larger samples (115 schizophrenic patients and 111 normal controls) than the original study and a method same as original study. A startle response monitoring system was used to deliver acoustic startle stimuli, and to record and score the electromyographic activity of the orbicularis oculi muscle. We evaluated the startle measures of mean magnitude of ASR, HAB, and PPI at prepulse sound pressure intensities of 82 dB (PPI82), 86 dB (PPI86), and 90 dB (PPI90). ASR was significantly different between schizophrenic patients and controls. HAB and all PPI session data from schizophrenic patients were significantly lower than in controls. In addition, we detected significant differences for ASR, HAB and each PPI (82, 86 and 90 dB) between schizophrenic patients and controls with the use of multiple regression analysis. The gender and smoking state were not correlated with ASR, HAB or any PPI in multiple regression analysis. In conclusion, we were able to replicate the finding of HAB impairment and PPI deficit in chronic Japanese schizophrenic patients.

© 2009 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

1. Introduction

Disruption of sensorimotor gating is considered to lead to abnormalities in cognitive dysfunction, such as attention-related information processing (Braff et al., 1992; McGhie and Chapman, 1961). Several investigations suggested that disruption of sensorimotor gating was measured mainly by prepulse inhibition (PPI) and the acoustic startle reflex (ASR) (Braff et al., 1992; Kunugi et al., 2007; Takahashi et al., 2008). PPI deficit, ASR and habituation (HAB) impairment are considered endophenotypes for schizophrenia (Braff et al., 1992; Kunugi et al., 2007; Takahashi et al., 2008; Walters and Owen, 2007).

Recently, Kunugi et al. (2007) have reported that a PPI deficit was detected in Japanese schizophrenic patients. More recently, Takahashi et al. (2008) evaluated the startle measures of mean magnitude of ASR, HAB, and PPI at prepulse sound pressure intensities of 82, 86, and 90 dB, respectively. Although they found that ASR was not significantly different between the patients and controls, they reported that patients showed significantly reduced HAB and PPI for all prepulse intensities compared to controls (Takahashi et al., 2008). In this study, we performed a replication using larger samples (115 schizophrenic patients and 111 normal controls) than the original study and a method same as original study (Takahashi et al., 2008).

2. Materials and methods

2.1. Subjects

One hundred and fifteen schizophrenic patients (71 males and 40 females: mean age \pm standard deviation (SD) 52.0 \pm 1.46 years)

* Corresponding author at: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. Tel.: +81 562 93 9250; fax: +81 562 93 1831.

E-mail address: tarok@fujita-hu.ac.jp (T. Kishi).

¹ These authors contributed equally to this work.

and 111 normal controls (72 males and 38 females; mean age \pm standard deviation (SD) 32.7 ± 0.674 years) were recruited. All subjects were unrelated to each other, ethnically Japanese, and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with the consensus of at least two experienced psychiatrists on the basis of a structured interview using the Structured Clinical Interview for DSM-IV disorders (SCID-1) and a review of medical records. All the patients met the following inclusion criteria: (1) age 25–70 years, (2) no systemic or neurologic disease, (3) no electroconvulsive therapy, (4) no history of head trauma, (5) no lifetime history of substance dependence or history of substance abuse within 3 months and (6) maintenance of main antipsychotic drug therapy for 2 months. All healthy control subjects were also psychiatrically screened based on structured interviews. None had severe medical complications or other Axis-I disorders according to DSM-IV using SCID-1. No structured methods were used to assess psychiatric symptoms in the controls. The study was described to subjects and written informed consent was obtained from each. This study was approved by the ethics committees at Fujita Health University School of Medicine and Okehazama Hospital.

2.2. Startle response measurement

2.2.1. Apparatus and stimuli

We measured startle measure using a commercial computerized human startle response monitoring system (Startle Eyeblink Reflex Analysis System Map1155SYS, Nihonsanteku Co., Osaka, Japan). Startle eyeblink electromyographic responses were recorded from the left orbicularis oculi muscle with 2 Ag/AgCl disposable electrodes (sensor area 15 mm^2) filled with wet gel. The first electrode (Blue Sensor N-00-S, Ambu, Ballerup, Denmark) was positioned approximately 1 cm directly below the pupil of the left eye and low enough to not touch the lower eyelid, while the second electrode (Blue Sensor M-00-S, Ambu, Ballerup, Denmark) was placed laterally and slightly superior to the first one, with the centers of the electrodes separated by approximately 2 cm. The impedance between the two electrodes was measured and deemed acceptable if below 5 k Ω . The impedance was measured with an electrode impedance meter (MaP811, Nihonsanteku Co., Osaka, Japan) at a measurement frequency = 30 Hz. The ground electrode (Blue Sensor M-00-S) was placed on the left angle of the mandible. We used a method same as Takahashi et al.'s (2008) study. Detailed information can be seen in Takahashi et al.'s (2008) paper.

2.2.2. The stimulus sequence, procedure and response scoring and data reduction

Measurements were made with startle paradigm constructed of 3 blocks with continuous 70 dB SPL background white noise. Pulse stimuli consisted of broadband white noises with an instantaneous rise/fall time lasting for 40 ms and presented at 115 dB SPL. Prepulse stimuli were also broadband white noises with an instantaneous rise/fall time lasting for 20 ms and presented at three different intensities (82, 86, and 90 dB SPL). The lead interval (LI) (from prepulse onset to pulse onset) in our study was set at 120 ms. In block 1, the startle response for pulse alone trials (PA trial) was recorded 6 times. Block 2 consisted of PA trials or trials of pulse with prepulse at three intensities (PP trials), performed eight times for each condition. Block 3 was the same as block 1 to measure the habituation phenomenon. All trials were presented in a fixed pseudorandom order, separated by inter-trial intervals of 15–25 s (20 s on average). The startle paradigm consisted of a total of 44 trials. Together with 5 min acclimation to the background noise, the session lasted approximately 20 min. We used a method same as Takahashi et al.'s (2008) study. Detailed information can be seen in Takahashi et al.'s (2008) paper.

2.3. Statistical analysis

Individual *t* test and chi-square tests (Fisher's exact test when appropriate) were used to compare means and categorical proportions, respectively. All PPI measures were examined with analysis of variance (ANOVA) with repeated measures of prepulse intensities. In addition, because several investigators have reported significant differences in startle response with gender difference, between smokers and nonsmokers, and with the effect of benzodiazepine in not only schizophrenic patients but also normal controls (Kumari et al., 2004, 1996, 1997; Swerdlow et al., 1999), we performed exploratory analysis of the possible correlations between all startle measures (PPI, ASR and HAB, respectively) and diagnosis (schizophrenia or controls), gender, and smoking history (smoker or nonsmoker) by multiple regression analysis. In these analyses, all startle measures were set as the dependent variable, and diagnosis (schizophrenia or controls), gender and current smoking status (smoker or nonsmoker) were set as the independent variables. We performed another multiple regression analysis on the effect of several clinical variables on all startle measures with schizophrenic patients. In these analyses, all startle measures were set as the dependent variable, and age, duration of illness, gender, smoking status, and medication dosage (antipsychotics and anxiolytics/hypnotics) were set as the independent variables. The significance level for all statistical tests was 0.05.

All statistical analyses were performed using JMP (JMP 5.0. 1J, SAS Japan Inc., Tokyo, Japan).

3. Results

3.1. Patient and control demographics and disposition

Among the subjects (schizophrenia or controls) in this study, only one difference with recruited age was detected (P value ≤ 0.0001) (Table 1). Also, there were 15 nonresponders in the patient group and 4 in the control group. Therefore, we performed the analysis of startle measure with 100 patients and 107 controls. Clinical demographics and disposition of analysed schizophrenic patients are shown in Table 1.

3.2. Schizophrenic patients vs. controls

We detected significant differences for all startle measures between schizophrenic patients and controls (Fig. 1). In addition, we detected significant differences for ASR, HAB and each PPI (82, 86 and 90 dB) between schizophrenic patients and controls with the use of multiple regression analysis (Table 2). The gender and smoking state were not correlated with ASR, HAB or any PPI in multiple regression analysis (Table 2).

3.3. Startle response with schizophrenia reflected clinical variables

There was no significant correlation of ASR, HAB or any PPI for either side with age, duration of illness, gender, smoking status, and medication dosage (antipsychotics and anxiolytics/hypnotics) (data not shown).

4. Discussion

We investigated startle response with schizophrenic patients and controls using larger samples than the original study. We were able to replicate HAB impairment and PPI deficit in chronic Japanese schizophrenic patients using a multiple regression model, controlling for other parameters known to influence the startle measure. To our knowledge, this type of analysis has not been previously used for startle response study. Controlling for

Table 1
Patients and controls demographics and disposition.

| | Participated control subjects | Participated schizophrenia subjects | P value ^a |
|--|-------------------------------|-------------------------------------|----------------------|
| N | 111 | 115 | |
| Current smoker/nonsmoker | 42 (37.4%) | 32 (27.8%) | 0.0791 |
| Sex (males/females) | 72/38 | 71/40 | 0.513 |
| Age, years (mean ± SD) | 32.7 ± 0.674 | 52.0 ± 1.46 | <0.0001 |
| | Analysed control subjects | Analysed schizophrenia subjects | P value ^a |
| N | 107 | 100 | |
| Current smoker/nonsmoker, n (%) | 40/67 (62.6) | 26/74 (26.0) | 0.0781 |
| Sex (males/females) | 71/36 | 62/38 | 0.514 |
| Age, years (mean ± SD) | 32.7 ± 7.16 | 51.6 ± 15.7 | <0.0001 |
| Duration of illness (day, mean ± SD) | | 9750 ± 524 | |
| Clinical diagnosis, n (%) | | | |
| Paranoid type | | 30 (30) | |
| Disorganeized type | | 9 (9) | |
| Residual type | | 61 (61) | |
| PANSS total score | | 77.1 ± 23.5 | |
| Medication dosage | | | |
| Antipsychotics (mg/day) ^b | | 693 ± 48.3 | |
| Antiparkinsonian drugs, n (%) | | 0 (0) | |
| Mood stabilizers, n (%) | | 21 (21) | |
| Anxiolytics/hypnotics, n (%) (mg/day) ^c | | 69 (69) (8.46 ± 9.51) | |

^a Bold represents significant P value.^b Chlorpromazine-equivalent.^c Diazepam-equivalent.

important covariates, we found that startle response changes did not differ with smoking status or gender. We showed that the only factor influencing startle measure was diagnosis (schizophrenia or controls). None of the startle measures in schizophrenic patients was correlated with age, duration of illness, gender, smoking status, or medication dosage (antipsychotics and anxiolytics/

hypnotics). Therefore, we considered that startle response might have diagnosis specificity associated with sensorimotor gating deficit.

Kunugi et al. (2007) reported reduced ASR and PPI despite of no reduced HAB in schizophrenia. On the other hand, Takahashi et al. (2008) reported reduced PPI and HAB despite of no reduction of




Fig. 1. ANOVA of startle measures with schizophrenia and controls. * $P < 0.05$, ** $P < 0.01$. (1) Acoustic startle reflex (ASR) (μV , mean \pm SD); schizophrenia: 78.0 ± 67.6 ; controls: 124 ± 96.5 . (2) Habituation (HAB) (% mean \pm SD); schizophrenia: 39.8 ± 26.0 ; controls: 48.6 ± 21.7 . (3) Prepulse inhibition (PPI); PPI 82 (% mean \pm SD); schizophrenia: 23.3 ± 30.2 ; controls: 33.0 ± 29.9 . PPI 86 (% mean \pm SD); schizophrenia: 32.0 ± 31.7 ; controls: 43.8 ± 26.2 . PPI 90 (% mean \pm SD); schizophrenia: 35.5 ± 31.5 ; controls: 53.1 ± 25.3 .

Table 2

Multiple regression analysis of startle measure with clinical variables. All startle measures were set as the dependent variable, and diagnosis (schizophrenia or controls), gender and current smoking status (smoker or nonsmoker) were set as the independent variables.

| Startle measure ^a | Clinical variables ^b | P value ^c | SRC ^d |
|------------------------------|---------------------------------|----------------------|------------------|
| ASR | Diagnosis | < 0.0001 | 0.402 |
| | Current smoker/nonsmoker | 0.189 | 0.0480 |
| | Sex | 0.591 | 0.110 |
| Habituation | Diagnosis | 0.0194 | 0.177 |
| | Current smoker/nonsmoker | 0.264 | −0.0879 |
| | Sex | 0.294 | 0.0820 |
| PPI 82db | Diagnosis | 0.0249 | 0.163 |
| | Current smoker/nonsmoker | 0.107 | 0.124 |
| | Sex | 0.0756 | −0.136 |
| PPI 86db | Diagnosis | 0.00350 | 0.212 |
| | Current smoker/nonsmoker | 0.174 | 0.181 |
| | Sex | 0.0818 | −0.132 |
| PPI 90db | Diagnosis | < 0.0001 | 0.310 |
| | Current smoker/nonsmoker | 0.0652 | 0.139 |
| | Sex | 0.428 | −0.0592 |

^a ASR: acoustic startle reflex; PPI: prepulse inhibition.

^b Diagnosis: schizophrenia or controls.

^c Bold represents significant P value.

^d SRC: standardized regression coefficient.

ASR in schizophrenia. In this study, we detected significant differences for all of ASR, HAB and each PPI (82, 86 and 90 dB) between schizophrenic patients and controls with the use of multiple regression analysis. We considered that the difference of some results in these studies might be the following reasons: (1) Taking different antipsychotic in patient group (Kumari and Sharma, 2002; Kumari et al., 2002; Wynn et al., 2007). Several studies showed the difference of the kind of the antipsychotics influenced startle response (Kumari and Sharma, 2002; Kumari et al., 2002; Wynn et al., 2007). (2) A difference of the numbers of the samples in each studies. Schizophrenic patients and healthy controls of Kunugi's study and Takahashi's study were reported to be 20 patients and 16 controls, and 51 patients and 55 controls, respectively (Kunugi et al., 2007; Takahashi et al., 2008). We replicated this study using larger samples (115 schizophrenic patients and 111 normal controls) than the two original studies (Kunugi et al., 2007; Takahashi et al., 2008).

A few points of caution should be noted in interpreting our results. First, the significant association may be due to biased samples, such as unmatched age samples. We were apprehensive that the age might influence ASR, HAB and all PPI. Therefore, we performed another exploratory analysis of the possible correlations between all startle measures (PPI, ASR and HAB, respectively) and diagnosis (schizophrenia or controls), age, gender, and smoking history (smoker or nonsmoker) by multiple regression analysis for confirmation. However, the gender, age and smoking state were not correlated with ASR, HAB or any PPI in multiple regression analysis (data not shown). Second, 21 patients needed to take mood stabilizers such as valproic acid and carbamazepine. Since a recent animal study using DBA/2NCR1 mice reported that

mood stabilizers increased PPI (Flood et al., 2009), our results for these 21 schizophrenic patients may have been influenced by the mood stabilizers.

In conclusion, we were able to replicate the HAB impairment and PPI deficit in chronic Japanese schizophrenic patients. However, because our samples are small, it will be necessary to conduct a longer term replication study using a larger patient group in the future.

Acknowledgements

We thank Mr. S. Maeda, Ms. E. Nakamura and Ms. M. Tojo for their technical support. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labor and Welfare, and the Japan Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.neures.2009.07.009.

References

- Braff, D.L., Grillon, C., Geyer, M.A., 1992. Gating and habituation of the startle reflex in schizophrenic patients. *Arch. Gen. Psychiatry* 49 (3), 206–215.
- Flood, D.G., Choinski, M., Marino, M.J., Gasior, M., 2009. Mood stabilizers increase prepulse inhibition in DBA/2NCR1 mice. *Psychopharmacology (Berl)* 205 (3), 369–377.
- Kumari, V., Aasen, I., Sharma, T., 2004. Sex differences in prepulse inhibition deficits in chronic schizophrenia. *Schizophr. Res.* 69 (2/3), 219–235.
- Kumari, V., Checkley, S.A., Gray, J.A., 1996. Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. *Psychopharmacology (Berl)* 128 (1), 54–60.
- Kumari, V., Cotter, P.A., Checkley, S.A., Gray, J.A., 1997. Effect of acute subcutaneous nicotine on prepulse inhibition of the acoustic startle reflex in healthy male non-smokers. *Psychopharmacology (Berl)* 132 (4), 389–395.
- Kumari, V., Sharma, T., 2002. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. *Psychopharmacology (Berl)* 162 (2), 97–101.
- Kumari, V., Soni, W., Sharma, T., 2002. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. *Schizophr. Res.* 55 (1/2), 139–146.
- Kunugi, H., Tanaka, M., Hori, H., Hashimoto, R., Saitoh, O., Hironaka, N., 2007. Prepulse inhibition of acoustic startle in Japanese patients with chronic schizophrenia. *Neurosci. Res.* 59 (1), 23–28.
- McGhie, A., Chapman, J., 1961. Disorders of attention and perception in early schizophrenia. *Br. J. Med. Psychol.* 34, 103–116.
- Swerdlow, N.R., Geyer, M.A., Hartman, P.L., Sprock, J., Auerbach, P.P., Cadenhead, K., Perry, W., Braff, D.L., 1999. Sex differences in sensorimotor gating of the human startle reflex: all smoke? *Psychopharmacology (Berl)* 146 (2), 228–232.
- Takahashi, H., Iwase, M., Ishii, R., Ohi, K., Fukumoto, M., Azechi, M., Ikezawa, K., Kurimoto, R., Canuet, L., Nakahachi, T., Iike, N., Tagami, S., Morihara, T., Okochi, M., Tanaka, T., Kazui, H., Yoshida, T., Tanimukai, H., Yasuda, Y., Kudo, T., Hashimoto, R., Takeda, M., 2008. Impaired prepulse inhibition and habituation of acoustic startle response in Japanese patients with schizophrenia. *Neurosci. Res.* 62 (3), 187–194.
- Walters, J.T., Owen, M.J., 2007. Endophenotypes in psychiatric genetics. *Mol. Psychiatry* 12 (10), 886–890.
- Wynn, J.K., Green, M.F., Sprock, J., Light, G.A., Widmark, C., Reist, C., Erhart, S., Marder, S.R., Mintz, J., Braff, D.L., 2007. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. *Schizophr. Res.* 95 (1–3), 134–142.

Orphan Nuclear Receptor Rev-erb Alpha Gene (*NR1D1*) and Fluvoxamine Response in Major Depressive Disorder in the Japanese Population

Taro Kishi^a Tsuyoshi Kitajima^a Masashi Ikeda^a Yoshio Yamanouchi^a
Yoko Kinoshita^a Kunihiro Kawashima^a Tomo Okochi^a Norio Ozaki^b
Nakao Iwata^a

^aDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, and ^bDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan

Key Words

Major depressive disorder · Orphan nuclear receptor Rev-erb α gene, *NR1D1* · Fluvoxamine · Linkage disequilibrium · Tagging SNP · Clock genes · Circadian rhythm

Abstract

Background: Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively influences clinical status. Treatment with antidepressants also reportedly affects circadian rhythms. In a recent in vitro study, the nuclear receptor Rev-erb α was reported to be related to circadian rhythms, and was shown to be involved in the biological action of lithium therapy. Therefore, we examined the association between the orphan nuclear receptor Rev-erb α gene (*NR1D1*) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder. **Methods:** The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in *NR1D1* for the following associa-

tion analysis. **Results:** We did not detect a significant association between *NR1D1* and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. **Conclusion:** Our results suggest that *NR1D1* does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.

Copyright © 2009 S. Karger AG, Basel

Introduction

Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively affects the clinical status of patients. It has been suggested that abnormalities in circadian rhythms are related to the pathophysiology of MDD [1, 2]. The evidence for this relation has been discussed in more detail in our previous paper [3] and a review by Barnard and Nolan [4].

Selective serotonin reuptake inhibitors (SSRIs), which are major therapeutic agents for MDD, act on the presynaptic neurons to increase the extracellular serotonin level, and this mechanism is believed to relieve depressive

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2009 S. Karger AG, Basel
0302-282X/09/0594-0234\$26.00/0

Accessible online at:
www.karger.com/nps

Taro Kishi, PhD
Department of Psychiatry
Fujita Health University School of Medicine
Toyoake, Aichi 470-1192 (Japan)
Tel. +81 562 93 9250, Fax +81 562 93 1831, E-Mail tarok@fujita-hu.ac.jp

symptoms. However, serotonin affects circadian rhythms [5], and SSRIs have also been reported to have circadian properties: SSRIs have a phase-shifting effect in rat suprachiasmatic nucleus neural firing [6] and change the expression of clock genes in the striatum and hippocampus of mice [7], suggesting that the SSRIs' antidepressant action also may be attributable to circadian mechanisms. In addition, the clock gene was reported to be associated with greater severity of insomnia during antidepressant treatment, a higher recurrence rate and reduced need for sleep in bipolar disorder patients [8–10]. Therefore, we considered that clock genes might be therapeutic targets of SSRIs.

In the mammalian circadian feedback loop, it is known that the CLOCK/Bmal1 heterodimer drives the transcription of multiple clock genes including *Cry*, *Per* and *Rev-erb α* gene (*NR1D1*) through E-box elements (detailed evidence for the molecular clock mechanism in mammals has been discussed in several reviews [4, 11–13]). Recently, orphan nuclear receptor Rev-erb α and glycogen synthase kinase-3 β (GSK-3 β) were shown to be important circadian components [14]. Orphan nuclear receptor Rev-erb α , which belongs to the rev-erb family of transcription factors called 'orphan nuclear receptors', is a key negative-feedback regulator of the circadian clock, and is itself expressed in a circadian manner that is finely controlled both transcriptionally and post-transcriptionally [14, 15]. For example, orphan nuclear receptor Rev-erb α represses Bmal1 gene transcription [15]. Yin et al. [14] showed that orphan nuclear receptor Rev-erb α is a target of GSK-3 β kinase activity, which is needed to mediate the regulation of circadian rhythms. These authors also found that in cultured mammalian cells, lithium treatment leads to rapid proteasomal degradation of Rev-erb α and subsequent activation of the Bmal1 gene, a clock gene [14]. Therefore, we thought that *NR1D1* was a good candidate gene for the pathophysiology of mood disorders, and performed an association analysis of *NR1D1* and mood disorders in the Japanese population [3]. No association was found [3], suggesting the possibility that MDD and the antidepressant treatment response in MDD do not have common susceptibility genes. Evidence in support of this hypothesis has been reported (e.g. *DTNBP1* and *NGFR*) [16, 17]. Therefore, although *NR1D1* was not found to play a major key role in the pathophysiology of mood disorders [3], we considered that *NR1D1* might be a susceptibility gene for SSRI treatment response.

In the present study, we examined the association between *NR1D1* and the efficacy of fluvoxamine treatment in Japanese MDD patients.

Materials and Methods

Subjects

The subjects were 118 MDD patients (59 males and 59 females; mean age \pm SD 44.5 \pm 16.5 years). All subjects were unrelated to each other, ethnically Japanese and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with consensus of at least 2 experienced psychiatrists on the basis of a review of medical records. Although these subjects were part of the MDD subject group in our previous study [3], all MDD patients in this study have specific characteristics: being treated with fluvoxamine and undergone a semi-structured interview for assessment of treatment response. Detailed information can be seen in 'Data collection'.

Fluvoxamine was taken 2 or 3 times a day for 8 weeks. The initial total dose in 1 day was 50–100 mg. Fluvoxamine was increased gradually to a maximum of 150 mg, depending on the patient's condition. Patients with insomnia and severe anxiety were prescribed benzodiazepine drugs, but no other psychotropic drugs were permitted during the study. The study was described to subjects and written informed consent was obtained from each participant. This study was approved by the Ethics Committee at Fujita Health University.

Data Collection

The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher [18]. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Detailed information on data collection was described in a previous paper [19]. The clinical characteristics of patients in this study, classified according to these definitions, can be seen in table 1.

SNP Selection and Linkage Disequilibrium Evaluation

We first consulted the HapMap database (release 20/phase II, Jan 2006, www.hapmap.org; population: Japan Tokyo, minor allele frequencies of >0.05) and included 5 SNPs covering *NR1D1* [5'-flanking regions including about 750 bp from the initial exon and about 1 kb downstream (3') from the last exon: HapMap database contig number chr17: 35501880–35510616]. Then 3 tagging SNPs were selected with the criteria of r^2 threshold greater than 0.8 in 'pair-wise tagging only' mode using the Tagger program (Paul de Bakker, www.broad.mit.edu/mpg/tagger) in Haploview [20]. These 3 tagging SNPs (rs939347, rs2071427 and rs3744805) were used for the following association analysis. Detailed information can be seen in our previous paper [3].

SNP Genotyping

We used TaqMan assays (Applied Biosystems, Foster City, Calif., USA) for all SNPs. Detailed information can be seen in our previous paper [3].

Statistical Analysis

Genotype deviation from the Hardy-Weinberg equilibrium was evaluated by the χ^2 test (SAS/Genetics, version 8.2, SAS Japan, Tokyo, Japan).

Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the χ^2 test or Fisher's exact

Table 1. Clinical characteristics of the patients in both groups

| | Total | Males | Females | Age years | Baseline SIGH-D | Fluvoxamine dose at 8 weeks mg/day | Number of previous episodes |
|---------------------------------------|-------|-------|---------|-------------|-----------------|------------------------------------|-----------------------------|
| Overall | 118 | 59 | 59 | 44.5 ± 16.5 | 20.2 ± 5.88 | 122 ± 40.9 | 1.39 ± 0.658 |
| Clinical response group ¹ | | | | | | | |
| Responders | 59 | 31 | 28 | 44.4 ± 16.3 | 21.5 ± 6.19 | 118 ± 41.1 | 1.36 ± 0.574 |
| Nonresponders | 59 | 28 | 31 | 44.3 ± 17.3 | 18.8 ± 5.28 | 125 ± 40.7 | 1.43 ± 0.774 |
| p value | | 0.644 | | 0.801 | 0.0145 | 0.391 | 0.480 |
| Clinical remission group ² | | | | | | | |
| Remitters | 45 | 22 | 23 | 43.7 ± 15.9 | 19.6 ± 5.06 | 113 ± 43.9 | 1.37 ± 0.598 |
| Nonremitters | 73 | 37 | 36 | 45.1 ± 17.1 | 20.5 ± 6.34 | 127 ± 38.2 | 1.41 ± 0.715 |
| p value | | 0.757 | | 0.750 | 0.750 | 0.101 | 0.856 |

Average values presented with SD. ¹ A decrease of ≥50% in baseline SIGH-D score. ² Final SIGH-D score <7.

test (SAS/Genetics), and haplotype-wise association analysis was conducted with a likelihood ratio test using the Cocophase 2.403 program [21]. The power calculation was performed using the Genetic Power Calculator [22]. In addition, we included another test for the association between percentage decrease from baseline to the end of the period of observation at the SIGH-D score and each tagging SNP genotype data, with analysis of covariance (ANCOVA) using the least-squares method. Gender, age at the time of recruitment, fluvoxamine dose at 8 weeks and SIGH-D total score at the baseline were covariates used in the analysis to better model the effect of genotype on percentage decrease from baseline to the end of the period of observation at the SIGH-D score. The statistical package JMP for Windows was used for ANCOVA (JMP 5.0. 1J, SAS). Bonferroni's correction was used to control inflation of the type I error rate. The significance level for all statistical tests was 0.05.

Results

Among the clinical characteristics of patients in this study, only 1 difference with total SIGH-D score at the baseline was detected ($p = 0.0145$; table 1). Genotype frequencies of all SNPs were in Hardy-Weinberg equilibrium. We did not detect an association between *NR1D1* and the fluvoxamine therapeutic response in MDD in the allele/genotype-wise analysis (table 2) or the haplotype analysis (response: $p = 0.695$, and remission: $p = 0.384$). Also, ANCOVA was performed to test the effect of the tagging SNP genotype at percentage decrease from baseline to the end of the period of observation with the SIGH-D score when MDD patients were treated with fluvoxamine. There were no statistically significant differences in the change in percentage decrease from baseline

to the end of the period of observation with the SIGH-D score in which there was a fluvoxamine response to *NR1D1* genotype (rs939347: $p = 0.434$, rs2071427: $p = 0.891$, and rs3744805: $p = 0.450$).

Discussion

We first performed an association analysis of clock genes with fluvoxamine response in MDD patients. However, we did not detect a significant association between *NR1D1* and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. In addition, we performed another test for the differences in percentage decrease from baseline to the end of the period of observation. In this test, we used the SIGH-D score among the data for each tagging SNP genotype that was evaluated by ANCOVA after adjustment for sex, age at the time of recruitment, fluvoxamine dose at 8 weeks and SIGH-D total score at the baseline. No association was found. Therefore, our results suggest that *NR1D1* does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients.

We recently reported that *NR1D1* does not play a major role in the pathophysiology of Japanese MDD patients [3]. We consider that the present study strongly supports our previous study. However, because 1 of the biological actions of lithium treatment has been reported to affect the expression of clock genes mediated by Rev-erb α in vitro [14], the pharmacogenomics of bipolar disorder (lithium response) and gene-gene interactions among clock genes will also need to be investigated in the future.

Table 2. Genotype and allele distributions of *NR1D1* in both groups

| SNP ID (major allele → minor allele) | Clinical groups | Minor allele frequency | n | Genotype distribution | | | HWE | p value (HWE) | |
|--------------------------------------|-----------------|------------------------|----|-----------------------|-----|-----|-------|---------------|--------|
| | | | | M/M | M/m | m/m | | genotype | allele |
| rs939347 | responders | 0.551 | 59 | 14 | 25 | 20 | 0.270 | | |
| G → A | nonresponders | 0.475 | 59 | 16 | 30 | 13 | 0.880 | 0.355 | 0.241 |
| | remission | 0.522 | 45 | 12 | 19 | 14 | 0.302 | | |
| | nonremission | 0.507 | 73 | 18 | 36 | 19 | 0.908 | 0.740 | 0.818 |
| rs2071427 | responders | 0.542 | 59 | 11 | 32 | 16 | 0.477 | | |
| A → G | nonresponders | 0.483 | 59 | 15 | 31 | 13 | 0.689 | 0.625 | 0.362 |
| | remission | 0.500 | 45 | 12 | 21 | 12 | 0.655 | | |
| | nonremission | 0.521 | 73 | 14 | 42 | 17 | 0.192 | 0.483 | 0.759 |
| rs3744805 | responders | 0.424 | 59 | 20 | 28 | 11 | 0.828 | | |
| A → G | nonresponders | 0.483 | 59 | 15 | 31 | 13 | 0.689 | 0.596 | 0.360 |
| | remission | 0.478 | 45 | 14 | 19 | 12 | 0.302 | | |
| | nonresponders | 0.438 | 73 | 21 | 40 | 12 | 0.335 | 0.307 | 0.555 |

M = Major allele; m = minor allele; HWE = Hardy-Weinberg equilibrium.

It will also be important to investigate the association between other clock genes and SSRIs response in MDD using larger samples.

A few points of caution should be noted in interpreting our results. Firstly, our sample sizes were small. We obtained power of more than 80% for the detection of association when we set the genotype relative risk at 1.55–1.85 in all 118 samples, under a multiplicative model of inheritance [22]. Therefore, a replication study using a larger sample may be required for conclusive results. Secondly, we did not include a mutation scan to detect rare variants with functional effects. However, it is difficult to evaluate the association of such extremely rare variants (e.g. minor allele frequencies of less than 0.01) from the viewpoint of power. Furthermore, the analysis of copy number variation, acetylation and methylation rates in *NR1D1* were not analyzed in our study.

In conclusion, our results suggest that *NR1D1* does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and larger sample will be required for conclusive results.

Acknowledgments

We thank Ms. M. Miyata and Ms. S. Ishihara for their technical support. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labor and Welfare, and the Japan Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation).

References

- 1 Healy D: Rhythm and blues: neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. *Psychopharmacology (Berl)* 1987; 93:271–285.
- 2 Ehlers CL, Frank E, Kupfer DJ: Social zeitgebers and biological rhythms: a unified approach to understanding the etiology of depression. *Arch Gen Psychiatry* 1988;45: 948–952.
- 3 Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Ozaki N, Iwata N: Association analysis of nuclear receptor Rev-erb alpha gene (*NR1D1*) with mood disorders in the Japanese population. *Neurosci Res* 2008;62:211–215.
- 4 Barnard AR, Nolan PM: When clocks go bad: neurobehavioural consequences of disrupted circadian timing. *PLoS Gen* 2008;4: e1000040.
- 5 Monteleone P, Maj M: The circadian basis of mood disorders: recent developments and treatment implications. *Eur Neuropsychopharmacol* 2008;18:701–711.
- 6 Sprouse J, Braselton J, Reynolds L: Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. *Biol Psychiatry* 2006;60:896–899.

- 7 Uz T, Ahmed R, Akhisaroglu M, Kurtuncu M, Imbesi M, Dirim Arslan A, Manev H: Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. *Neuroscience* 2005;134:1309–1316.
- 8 Benedetti F, Serretti A, Colombo C, Barbini B, Lorenzi C, Campori E, Smeraldi E: Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. *Am J Med Genet B Neuropsychiatr Genet* 2003;123B:23–26.
- 9 Serretti A, Benedetti F, Mandelli L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E: Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. *Am J Med Genet B Neuropsychiatr Genet* 2003;121B:35–38.
- 10 Serretti A, Cusin C, Benedetti F, Mandelli L, Pirovano A, Zanardi R, Colombo C, Smeraldi E: Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. *Am J Med Genet B Neuropsychiatr Genet* 2005;137B:36–39.
- 11 Duez H, Staels B: Rev-erb alpha gives a time cue to metabolism. *FEBS letters* 2008;582:19–25.
- 12 Burris TP: Nuclear hormone receptors for heme: Rev-erb α and Rev-erb β are ligand-regulated components of the mammalian clock. *Mol Endocrinol* 2008;22:1509–1520.
- 13 Yin L, Wu N, Curtin JC, Qatanani M, Szewgold NR, Reid RA, Waitt GM, Parks DJ, Pearce KH, Wisely GB, Lazar MA: Rev-erb α , a heme sensor that coordinates metabolic and circadian pathways. *Science* 2007;318:1786–1789.
- 14 Yin L, Wang J, Klein PS, Lazar MA: Nuclear receptor Rev-erb α is a critical lithium-sensitive component of the circadian clock. *Science* 2006;311:1002–1005.
- 15 Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, Schibler U: The orphan nuclear receptor rev-erb α controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* 2002;110:251–260.
- 16 Arias B, Serretti A, Mandelli L, Gasto C, Catalan R, Ronchi DD, Fananas L: Dysbindin gene (*DTNBPI*) in major depression: association with clinical response to selective serotonin reuptake inhibitors. *Pharmacogenet Genomics* 2009;19:121–128.
- 17 Gau YT, Liou YJ, Yu YW, Chen TJ, Lin MW, Tsai SJ, Hong CJ: Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B:594–599.
- 18 Peveler R, Kendrick T: Selective serotonin reuptake inhibitors: THREAD trial may show way forward. *BMJ* 2005;330:420–421.
- 19 Saito S, Takahashi N, Ishihara R, Ikeda M, Suzuki T, Kitajima T, Yamanouchi Y, Iwata N, Yamada M, Yoshida K, Inada T, Ozaki N: Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. *Neuropsychobiology* 2006;54:226–230.
- 20 Barrett JC, Fry B, Maller J, Daly MJ: Haplotype analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–265.
- 21 Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. *Genet Epidemiol* 2003;25:115–121.
- 22 Purcell S, Cherny SS, Sham PC: Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 2003;19:149–150.

Regular Article

Risk factors for obstructive sleep apnea syndrome screening in mood disorder patients

Miho Hattori, MD,^{1,2} Tsuyoshi Kitajima, MD, PhD,^{2*} Takahiro Mekata, MD,²
 Aya Kanamori, MD,² Mototaka Imamura, DDS, PhD,³ Hiroki Sakakibara, MD, PhD,⁴
 Yuhei Kayukawa, MD, PhD,⁵ Tamotsu Okada, MD, PhD⁶ and Nakao Iwata, MD, PhD¹

¹Department of Psychiatry, Okehazama Hospital, Departments of ²Psychiatry, ³Oral and Maxillofacial Surgery, and
⁴Internal Medicine, Fujita Health University, ⁵Nagoya Institute of Technology, Health Administration Center and ⁶Okada
 Clinic, Sleep Disorders Laboratory, Aichi, Japan

Aims: Previous studies have reported that the incidence of obstructive sleep apnea syndrome (OSAS) in patients with depression is higher than in the general population. We examined the risk factors to predict OSAS in mood disorder patients with depressive symptoms.

Method: We conducted polysomnography for patients who satisfied the following criteria: (i) diagnosis of major depressive disorder or bipolar disorder according to the Mini-International Neuropsychiatric Interview (MINI); (ii) a score of ≥ 10 on the Hamilton Rating Scale for Depression (HAM-D); (iii) fulfillment of either (a) or (b) below: (a) at least one of the following: severe snoring, witnessed apnea during sleep, excessive daytime sleepiness; (b) at least one of the following plus an oxygen desaturation index of $4\% \geq 5$ times/h by pulse oximeter: mild snoring, sleep disturbance, headache, high blood pressure. The patients with apnea hypopnea index ≥ 5 were diagnosed with OSAS.

Results: Of the 32 mood disorder patients who met the subject conditions, 59.4% had OSAS. The diagnosis rate with our criteria was significantly higher than the previously reported incidence of OSAS in patients with depression. There was no significant difference among diagnosis rates as to individual risk factors or the number of risk factors. A multiple regression test showed no significant association between apnea-hypopnea index and other clinical factors including depression severity.

Conclusion: The present results showed that OSAS can be detected at a remarkably higher rate by considering appropriate OSAS risk factors in mood disorder patients, and suggested that there is a high rate of undetected and therefore untreated OSAS among mood disorder patients.

Key words: depression, mood disorders, obstructive sleep apnea syndrome, risk factors, screening.

OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS) has attracted attention as a cause of various physical disorders, as well as traffic or industrial accidents and occupational difficulties due to

excessive daytime sleepiness and cognitive dysfunction. Depression and OSAS have many common symptoms, including sleep disturbance, general fatigue, decreased volition and judgment ability, and other various physical manifestations. Earlier studies have reported that the incidence of OSAS complications in cases of depression is about 11–18%, higher than in the general population.^{1,2} From this, one may predict that there is much untreated OSAS among depression patients, and it would be reasonable to assume that some of these cases are treated as

*Correspondence: Tsuyoshi Kitajima, MD, PhD, Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. Email: tsuyoshi@fujita-hu.ac.jp
 Specific field: neurophysiology and psychophysiology.
 Received 23 August 2008; revised 13 December 2008; accepted 19 January 2009.

treatment-resistant depression.³ There are also a number of reports of OSAS treatment that improved comorbid depressive symptoms.^{4,5} By identifying and treating OSAS in depression patients, therefore, it may be possible to alleviate not only the various symptoms that accompany OSAS and the deterioration in quality of life, but also the depressive symptoms themselves.

Screening with the use of appropriate risk factors is needed for the easy detection of OSAS in the daily clinical setting. Reported risk factors for OSAS include sex, age, obesity, snoring and/or witnessed apnea during sleep, pharyngeal abnormalities, and cephalometric features.^{6–10} Some reports presented the usage of risk factors for OSAS prediction;^{6,8,11,12} however, there is lack of consensus, because the subjects of these previous studies were the general population. Additionally there has been no reported study on risk factors or screening for OSAS in mood disorder patients, as far as we know.

With the aim of identifying and treating OSAS in mood disorder patients presenting with depression, we conducted OSAS screening with known risk factors in these patients. And we examined whether the screening model in this study was useful and valid in the clinical setting of psychiatry, and which or how many risk factors would contribute most to OSAS screening.

METHODS

Subjects

Among patients who were treated for mood disorder in the departments of psychiatry at Fujita Health University Hospital and Okehazama Hospital, those who had no previous diagnosis of OSAS and who met the following criteria were selected as candidates for inclusion with high risk for latent OSAS, between April 2007 and March 2008.

Selection criteria

- 1 Diagnosis of major depressive disorder or bipolar disorder (in a major depressive episode) through a structured Mini-International Neuropsychiatric Interview (MINI) based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV); excluding untreated patients or patients in the acute phase whose drug regimen is being adjusted.

- 2 A score of ≥ 10 on the Hamilton Rating Scale for Depression (HAM-D).
- 3 Fulfillment of either (a) or (b) below.
 - (a) At least one of the following: severe snoring, witnessed apnea during sleep, or excessive daytime sleepiness.
 - (b) At least one of the following: mild snoring, sleep disturbance (arousal during sleep, unrefreshing sleep or mild daytime sleepiness), headache, or high blood pressure. In addition, oxygen desaturation index of 4% (ODI 4%) of ≥ 5 times per h, measured by a pulse oximeter.

Here, excessive daytime sleepiness is defined as drowsiness that interferes with social activities even though the patient feels that he or she received sufficient sleep. Pulse oximetry was carried out using Pulsox 6 (Minolta, Tokyo, Japan), a continuous, non-invasive arterial oxygen saturation monitor that was attached to one of the patient's fingers. The number of times that arterial oxygen saturation decreased by $\geq 4\%$ over one night was divided by the number of hours in bed to get the ODI 4%.

Assessment

Overnight polysomnography (PSG) was conducted according to the following procedure for patients who satisfied the above conditions. Patients with an apnea-hypopnea index (AHI) of ≥ 5 times per h were diagnosed as having OSAS that should be considered for treatment, according to the International Classification of Sleep Disorders 2nd edition (ICSD2). Hypnotics that have a muscle relaxant effect were discontinued before PSG, with the exception of short-acting ones. Also, benzodiazepines were discontinued in principle prior to examination, however, if the patients could not discontinue benzodiazepines because of symptoms such as anxiety, only the short-acting varieties were allowed to be continued. Other psychotropic drugs, including antidepressants and mood stabilizers, were continued.

Besides the HAM-D, we also conducted the Beck Depression Inventory (BDI), Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) for included subjects when they underwent PSG.

The study was approved by the ethics committees of Fujita Health University and Okehazama Hospital, and conducted after written explanations were given to all patients and their consent was obtained.

PSG

PSG was carried out following the procedure below, according to the clinical electroencephalography standards of the Japanese Society of Clinical Neurophysiology. Electroencephalogram (EEG), eye movement, chin electromyogram (EMG), expiration thermistor measurements, chest and abdominal expansion, electrocardiogram (ECG), arterial oxygen saturation, snoring, and leg EMG were recorded. Recordings from EEG electrodes were made at C3, C4, O1, and O2 according to the ten-twenty electrode system. A1 and A2 were placed at the bilateral mastoid processes as reference electrodes and connected to the contralateral cranial electrodes. For EMG, electrodes were attached 1 cm lateral and 1 cm superior to the lateral orbit margin of the left eye, and 1 cm lateral and 1 cm inferior to the lateral orbit margin of the right eye, with connections from two leads of these electrodes with the mastoid process A1 (single lead). For chin EMG, two electrodes were attached to the submental muscle, and for leg EMG two electrodes were attached to the tibialis anterior muscle and bipolar leads were used. ECG employed a CM5 lead. Measurements were made from 21.00 hours to 06.00 hours the following morning in an air-conditioned, sound insulated and dark room. The obtained signals were stored as digital data into a personal computer using one of two PSG systems, Alice 3 (Respironics, Murrysville, PA, USA) or Somnostar (Viasys, Conshohocken, PA, USA). The sleep stages and parameters were based on the criteria of Rechtschaffen and Kales, revised manually by trained technicians following automatic scoring by either PSG system. Apnea events were based on complete cessation or $\geq 50\%$ reduction of air flow of 10 sec or longer, and hypopnea events were the air flow reductions accompanied by SaO_2 reduction of $\geq 3\%$ or an arousal response when the reductions were $< 50\%$. The apnea or hypopnea counts were also revised manually by trained technicians after automatic scoring, and the mean number of both events per h divided by the total sleep time was taken as the AHI.

Statistical analysis

The χ^2 -test was conducted to verify the increase in the OSAS diagnosis rate for all cases included in this study based on the previously reported OSAS complication rate in depression. The difference in OSAS diagnosis rate in patients with each risk factor, and

the difference in OSAS diagnosis rate between patients with one risk factor and those with two or more risk factors, was compared using the χ^2 -test or Fisher's exact test. To test the relation between the other clinical factors and the severity of OSAS in the subject group, multiple regression analysis was conducted with AHI as the dependent variable and the clinical items (sex, age, psychiatric diagnosis, body mass index (BMI), ESS score, HAM-D score, BDI score, and PSQI score) as independent variables. Statistical calculations were conducted with JMP 5.0.1J computer software package (SAS Institute Japan, Tokyo, Japan). The significant level in the tests was set at $P < 0.05$.

RESULTS

Thirty-two subjects (24 men and eight women) met the screening criteria and were included in the study. The mean age of these patients was 48.4 ± 11.8 years. The psychiatric diagnosis was major depressive disorder in 19 and bipolar affective disorder in 13. Their mean HAM-D score was 15.69 ± 3.94 for 17 items. The risk factors matched for screening were witnessed apnea during sleep in six subjects, severe snoring in 21, excessive daytime sleepiness in 15, and mild symptoms plus ODI 4% of five or more times per h by pulse oximeter in four (multiple factors applied to some patients).

On PSG, 19 patients had OSAS of $\text{AHI} \geq 5$ ($\text{AHI} \geq 10$ in 15 patients, $\text{AHI} \geq 20$ in 10 patients). In the group with $\text{AHI} \geq 5$ (OSAS group), the risk factors matched for inclusion were witnessed apnea during sleep in five patients, severe snoring in 13, excessive daytime sleepiness in seven, and mild symptoms plus ODI 4% of ≥ 5 times/h by pulse oximeter in four (multiple factors applied to some patients). The OSAS group had 17 men and two women (Table 1). Setting the rate of complication with OSAS in mood disorder patients at 20%, which was higher than that from previous studies, the increase in the OSAS diagnosis rate was still statistically significant even when using the criterion of $\text{AHI} \geq 10$ from the present results ($P = 0.00005$).

The OSAS diagnosis rate for each risk factor in the patients included in the present study was as follows: OSAS was diagnosed in 83.3% (5/6) of patients with witnessed apnea during sleep, 61.9% (13/21) with severe snoring, and 46.7% (7/15) with excessive daytime sleepiness. Although no BMI inclusion criterion was considered in this screening, OSAS was diag-

Table 1. Demographic data and risk factors of the subjects

| | All patients | OSAS | | | Non-OSAS AHI < 5 | P-value |
|------------------------------------|--------------|-------------|-------------|-------------|------------------|---------|
| | | AHI ≥ 5 | AHI ≥ 10 | AHI ≥ 20 | | |
| <i>n</i> | 32 | 19 | 15 | 10 | 13 | |
| Sex (M/F) | 24/8 | 17/2 | 13/2 | 8/2 | 7/6 | 0.753 |
| Age | 48.4 ± 11.8 | 51.3 ± 12.2 | 53.1 ± 12.4 | 53.8 ± 13.4 | 44.2 ± 10.2 | 0.186 |
| Diagnosis (MDD/BD) | 19/13 | 10/9 | 8/7 | 5/5 | 9/4 | 0.503 |
| BMI (kg/m ²) | 27.2 ± 5.2 | 26.5 ± 5.3 | 26.2 ± 5.7 | 26.9 ± 6.7 | 28.1 ± 5.2 | 0.114 |
| ESS (score) | 7.6 ± 5.2 | 6.7 ± 5.6 | 5.9 ± 5.0 | 6.4 ± 5.8 | 8.9 ± 4.4 | 0.255 |
| HAM-D (score) | 15.7 ± 3.9 | 14.8 ± 3.6 | 14.4 ± 5.4 | 15.3 ± 4.3 | 17.0 ± 4.16 | 0.978 |
| BDI (score) | 22.2 ± 10.9 | 21.7 ± 11.4 | 19.4 ± 9.7 | 18.6 ± 9.8 | 22.9 ± 10.4 | 0.114 |
| PSQI (score) | 11.8 ± 4.3 | 11.4 ± 3.8 | 11.5 ± 3.9 | 11.8 ± 4.3 | 12.2 ± 5.1 | 0.079 |
| Risk factors | | | | | | |
| Apnea (<i>n</i>) | 6 | 5 | 3 | 2 | 1 | – |
| Snore (<i>n</i>) | 21 | 13 | 10 | 7 | 8 | – |
| EDS (<i>n</i>) | 15 | 7 | 5 | 4 | 8 | – |
| ODI4% ≥ 5 (<i>n</i>) | 4 | 4 | 3 | 1 | 0 | – |
| [†] BMI > 25 (<i>n</i>) | 22 | 13 | 9 | 6 | 9 | – |

Data are shown by mean ± standard deviation. *P*-value shows the result of multiple regression test.

[†]BMI > 25 is not included in the screening major items.

AHI, apnea-hypopnea index; BD, bipolar disorder; BDI, Beck Depression Inventory; BMI, body mass index; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HAM-D, Hamilton Rating Scale for Depression; MDD, major depressive disorder; ODI, oxygen desaturation index.; OSAS, obstructive sleep apnea syndrome; PSQI, Pittsburgh Sleep Quality Index.

nosed in 59.1% (13/22) of patients with BMI > 25. All patients with mild symptoms plus ODI 4% of ≥5 times/h by pulse oximeter (4/4) were diagnosed with OSAS. By sex, OSAS was diagnosed in 69.6% (16/23) of men and 28.6% (2/7) of women. After excluding witnessed apnea during sleep and ODI 4% because there were too few of these items for statistical analysis, no significant difference was seen in the percentage of OSAS diagnosis between the three risk factors BMI > 25, severe snoring, and excessive daytime sleepiness (*P* = 0.638). OSAS was diagnosed in 57.9% (11/19) of patients who fulfilled only one of the inclusion criteria of severe snoring, excessive daytime sleepiness, witnessed apnea, and ODI 4%, and in 61.5% (8/13) of patients who fulfilled two or more; no significant difference was seen in these rates of diagnosis (*P* = 0.836). Adding BMI > 25 as a risk factor, which was not one of the inclusion criteria, the rate of diagnosis became 62.5% (5/8) of patients who fulfill only one criteria, and 58.3% (14/24) of patients who fulfill two or more; also no significant difference was seen between these two diagnostic rates (*P* = 1.00; Fisher's exact test).

In the multiple regression analysis, no significant relation was seen between AHI and any of the other clinical characteristics (Table 1).

DISCUSSION

Of the 32 mood disorder patients who met the subject conditions in the present study, 59.4% had OSAS. It has been reported that the prevalence of OSAS complications in depression patients is higher than that in healthy people. Kayukawa and Okada conducted PSG in 119 depression patients, and found that 11.8% had OSAS when the diagnostic criterion was AHI of ≥10.¹ It was also reported, from a cross-sectional study using telephone surveys of 18 980 subjects in England and four other European countries, that complications with sleep-related breathing disorders including OSAS were present in 18% of depression patients diagnosed according to DSM-IV.² In the screening conducted in the present study we were able to identify OSAS in 46.9% of subjects even using the criteria of AHI ≥ 10, which is remarkably and significantly greater than even a high estimate of a 20% complication rate with OSAS in mood disorder patients, based on the above previous reports. Therefore, we may consider that the screening criteria with the risk factors we employed in this study was an effective method of detecting OSAS in up to about half of mood disorder cases in a psychiatric clinical setting. Factors other than these risk

factors that may have contributed to raising the diagnosis rate are the inclusion of patients with bipolar disorder, and having ≥ 10 points on HAM-D as inclusion criteria. It is thought that a high proportion of bipolar disorder patients are overweight, and the possibility cannot be ruled out that the complication rate of OSAS is higher than in major depressive disorder patients. However, in our results there was no significant difference even though the OSAS diagnosis rate for bipolar disorder was slightly higher than that for monopolar major depressive disorder in this study (data not shown). Additionally, in subgroups of both major depressive disorder and bipolar disorder the OSAS diagnosis rate was significantly higher than 20% based on the criterion of AHI ≥ 10 (data not shown). Therefore, it is difficult to conclude that including bipolar disorder patients by itself led to a higher rate of OSAS diagnosis. In addition, one may consider that there would be more complications with OSAS in patient groups with high HAM-D scores, because of the possibility that the HAM-D score increases with the occurrence of arousals during sleep or other sleep disturbance in OSAS patients, or the possibility that depression itself is exacerbated by OSAS. However, in our results no significant correlation was seen between the HAM-D score and the AHI or OSAS diagnosis (described below), and so it seems unlikely that having a score of ≥ 10 on the HAM-D would greatly increase the diagnosis rate of OSAS. We have no direct verification of this, however, as we do not have data for the HAM-D of < 10 .

From the above, one may conclude that establishing the risk factors used in the present screening was effective in significantly raising the diagnosis rate. For the past several years we have had a special sleep clinic in the psychiatry department, and patients strongly suspected of OSAS have already undergone PSG and been treated before this study began. We conducted this screening excluding the patients already diagnosed with OSAS. Screening with the present risk factors revealed latent OSAS for which treatment may be required in about half of patients, which suggests that it may be worthwhile to conduct similar screening for OSAS in other psychiatric clinical settings as well.

Previous studies have indicated that risk factors for OSAS include sex, age, snoring, witnessed apnea during sleep, obesity, pharyngeal abnormalities, and cephalometric features.^{6–10} We selected risk factors from among these with the purpose of thorough and effective screening in daily clinical practice in the

psychiatric department. Excessive daytime sleepiness is a main symptom of OSAS, and it has been shown to be closely related to OSAS.¹³ Because it is used conventionally in daily clinical practice as a subjective symptom that does not require observation by others, we adopted it as the major item in the present screening. The indicators of severe snoring and witnessed apnea during sleep have been given as risk factors for OSAS in previous reports, which claim that they are the main symptoms of OSAS.^{8,10} Therefore, they were also adopted as the major items for screening. However, checking these items depends greatly on a patient's individual sleeping environment, particularly whether or not the patient has a bed partner, and so it would be very difficult to conduct screening with these items alone. Obesity, meanwhile, has been reported to have little usefulness as a risk factor for OSAS in the Asian population including the Japanese,^{14,15} and it was not included in the major screening items in this study. It has been noted that cephalometric features can replace obesity as a risk factor in the Japanese population,^{7,9} but cephalograms were not conducted as they are inconvenient for screening in the psychiatry clinic. Sex and age have been given as risk factors for OSAS,^{6,8,10,12} but OSAS cannot be suspected because of these factors alone and so they were not included as the major items in the present screening.

When these items were included in the screening, the OSAS diagnosis rate, in the order from the highest, was 83.3% (5/6) with witnessed apnea during sleep, 61.9% (13/21) with severe snoring, and 46.7% (7/15) with excessive daytime sleepiness. Although BMI > 25 was not included in the inclusion criteria, the diagnosis rate with it was 59.1% (13/22). No significant differences were seen between these diagnosis rates. Therefore, no evidence was discovered for arguing that the weight of the items should be changed for a more effective screening. However, there were only a small number of patients with witnessed apnea during sleep, so they were excluded from the statistical testing. It is possible that with more cases the diagnosis rate would be higher than with the other risk factors. Recent studies reported less predictive value of excessive daytime sleepiness for OSAS,^{8,16} and nonspecific daytime sleepiness from such as psychotropic drugs or the underlying disease itself may be stronger in mood disorder patients than in the general population. Although the diagnosis rate with excessive daytime sleepiness was lower than with other present risk factors, the difference was not

significant: even so, the possibility cannot be ruled out that with a greater number of cases it would be significantly lower.

ODI measured with a pulse oximeter has been reported to correlate with AHI to a certain extent, and there have also been several reports on methods to predict OSAS using pulse oximetry. However, there is a lack of agreement in the findings on the utility of this method. For example, one study supported the usefulness of pulse oximetry showing that the extent of the decline in SpO₂ and ODI were sufficiently comparable to PSG;¹⁷ however, other studies showed that the device succeeded to affirm the diagnosis of severe OSAS but overlooked mild or moderate OSAS.^{18,19} There is also a report on the difficulty of diagnosis by evaluation with pulse oximetry alone.²⁰ In the present study pulse oximetry was conducted for patients who did not have the above major risk factors but had at least one of the conditions of mild snoring or mild sleep disturbance (arousal during sleep, unrefreshing sleep or mild daytime sleepiness), headache, high blood pressure; so it was not performed in all cases. All of the present patients who exhibited ODI 4% \geq 5 times per h were diagnosed with OSAS, but as it was only seen in four included cases its efficacy cannot be compared with other risk factors. While it is possible that screening with pulse oximetry would detect a greater number of OSAS cases, regardless of the presence or absence of other risk factors and symptoms for OSAS, it would be virtually impossible to conduct pulse oximetry in almost all mood disorder patients in an actual clinical psychiatric practice. Conversely, it may be that the diagnostic efficiency could be raised by conducting pulse oximetry and excluding patients with an ODI below a certain level among candidates who already have other major risk factors. However, considering an increase in false negatives among patients with comparatively mild OSAS in the light of the device's measurement principles and the above reported results, it does not suit the purpose of screening, which is to reduce the number overlooked. Therefore, the present screening method, in which pulse oximetry was used in cases with weak symptoms of suspected OSAS other than the major risk factors, is thought to have a certain validity.

Whether the presence of multiple risk factors is more efficient for OSAS prediction than a single risk factor is of interest. Some studies have presented a predictive model for OSAS with combined risk factors;^{6,8,11,12} however, they still lack consensus and the

models are still inconvenient for daily clinical practice. Unexpectedly, our present results showed no significant difference in the diagnosis rate between cases with only one of the three major risk factors for inclusion and cases with more than one. Therefore, the presence of only one of these risk factors in screening is thought to have a uniform validity in strongly suspecting OSAS. Nor was there a significant difference between cases with one or multiple risk factors when the factor of BMI was included as a risk factor among the present cases, however no patients were included in the present study because of high BMI only, and so we cannot comment on the value of BMI alone as a major risk factor.

In a multiple regression analysis with the other clinical items as the independent variables and AHI as the dependent variable, no items showed a significant relation with AHI. This finding argues against the possibility that other specific factors contributed strongly to a diagnosis of OSAS in the cases included in the present study. It is worth noting that no correlation was seen between AHI and depressive severity according to BDI or HAM-D in the present subjects. Opinions are divided on the role of OSAS in depression,^{21–26} but the present results did not strongly support such a role.

One limitation in the present study was the small number of subjects. As mentioned above, the possibility cannot be ruled out that with a greater number of subjects some significant differences would be revealed among risk factors in their level of contribution to diagnosis. In this study we evaluated OSAS only in a group with risk factors; therefore, we cannot evaluate the sensitivity and specificity of this screening model. Pulse oximetry was conducted in only a small part of the patients, as noted above, and cephalograms were not obtained, so we could not evaluate these potential risk factors: However, to verify a screening model for 'real world' psychiatric clinical settings, it would seem to be meaningful that the evaluation was made using a rather practical form.

In summary, the present results showed that OSAS can be detected at a higher rate by considering appropriate OSAS risk factors in mood disorder patients, and suggested that there is a high rate of undetected and therefore untreated OSAS among mood disorder patients. Therapists involved in treating mood disorders should not overlook OSAS and at the same time need to be cautious in using drugs with a muscle relaxant effect such as benzodiazepines. They also need to pay attention to obesity, which can exacer-

bate OSAS. In the future we will need to conduct investigations with greater numbers of patients and verify whether or not improvements in depressive symptoms can be expected with treatment of detected OSAS.

ACKNOWLEDGMENTS

The authors would like to express their sincere appreciation to Ms. Fujita (technician) and everyone else in the sleep and breathing laboratory for their cooperation in this study.

REFERENCES

- Kayukawa Y, Okada T. What is the relationship between SAS and depression? *Himan To Tonyobyō* 2005; 4: 433–435 (in Japanese).
- Ohayon MM. The effects of breathing-related sleep disorders on mood disturbances in the general population. *J. Clin. Psychiatry* 2003; 64: 1195–1200; quiz, 1274–1276.
- Lee S, Wing YK, Chen CN. Obstructive sleep apnoea and depression. *Aust. N. Z. J. Psychiatry* 1993; 27: 165–166.
- Kawahara S, Akashiba T, Akahoshi T, Horie T. Nasal CPAP improves the quality of life and lessens the depressive symptoms in patients with obstructive sleep apnea syndrome. *Intern. Med.* 2005; 44: 422–427.
- Schwartz DJ, Kohler WC, Karatinos G. Symptoms of depression in individuals with obstructive sleep apnea may be amenable to treatment with continuous positive airway pressure. *Chest* 2005; 128: 1304–1309.
- Dixon JB, Schachter LM, O'Brien PE. Predicting sleep apnea and excessive day sleepiness in the severely obese: Indicators for polysomnography. *Chest* 2003; 123: 1134–1141.
- Kubota Y, Nakayama H, Takada T *et al.* Facial axis angle as a risk factor for obstructive sleep apnea. *Intern. Med.* 2005; 44: 805–810.
- Rodsutti J, Hensley M, Thakkinian A, D'Este C, Attia J. A clinical decision rule to prioritize polysomnography in patients with suspected sleep apnea. *Sleep* 2004; 27: 694–699.
- Sakakibara H, Tong M, Matsushita K, Hirata M, Konishi Y, Suetsugu S. Cephalometric abnormalities in non-obese and obese patients with obstructive sleep apnoea. *Eur. Respir. J.* 1999; 13: 403–410.
- Young T, Shahar E, Nieto FJ *et al.* Predictors of sleep-disordered breathing in community-dwelling adults: The Sleep Heart Health Study. *Arch. Intern. Med.* 2002; 162: 893–900.
- Gurubhagavatula I, Maislin G, Pack AI. An algorithm to stratify sleep apnea risk in a sleep disorders clinic population. *Am. J. Respir. Crit. Care Med.* 2001; 164: 1904–1909.
- Hoffstein V, Szalai JP. Predictive value of clinical features in diagnosing obstructive sleep apnea. *Sleep* 1993; 16: 118–122.
- Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: Prevalence, severity, and predictors. *Sleep Med.* 2004; 5: 339–343.
- Li KK, Kushida C, Powell NB, Riley RW, Guilleminault C. Obstructive sleep apnea syndrome: A comparison between Far-East Asian and white men. *Laryngoscope* 2000; 110: 1689–1693.
- Li KK, Powell NB, Kushida C, Riley RW, Adornato B, Guilleminault C. A comparison of Asian and white patients with obstructive sleep apnea syndrome. *Laryngoscope* 1999; 109: 1937–1940.
- Rosenthal LD, Dolan DC. The Epworth sleepiness scale in the identification of obstructive sleep apnea. *J. Nerv. Ment. Dis.* 2008; 196: 429–431.
- Magalang UJ, Dmochowski J, Veeramachaneni S *et al.* Prediction of the apnea–hypopnea index from overnight pulse oximetry. *Chest* 2003; 124: 1694–1701.
- Nijijima K, Enta K, Hori H, Sashihara S, Mizoue T, Morimoto Y. The usefulness of sleep apnea syndrome screening using a portable pulse oximeter in the workplace. *J. Occup. Health* 2007; 49: 1–8.
- Yamashiro Y, Kryger MH. Nocturnal oximetry: Is it a screening tool for sleep disorders? *Sleep* 1995; 18: 167–171.
- Golpe R, Jimenez A, Carpizo R, Cifrian JM. Utility of home oximetry as a screening test for patients with moderate to severe symptoms of obstructive sleep apnea. *Sleep* 1999; 22: 932–937.
- Millman RP, Fogel BS, McNamara ME, Carlisle CC. Depression as a manifestation of obstructive sleep apnea: Reversal with nasal continuous positive airway pressure. *J. Clin. Psychiatry* 1989; 50: 348–351.
- Pillar G, Lavie P. Psychiatric symptoms in sleep apnea syndrome: Effects of gender and respiratory disturbance index. *Chest* 1998; 114: 697–703.
- Aikens JE, Mendelson WB. A matched comparison of MMPI responses in patients with primary snoring or obstructive sleep apnea. *Sleep* 1999; 22: 355–359.
- Aloia MS, Arnedt JT, Smith L, Skrekas J, Stanchina M, Millman RP. Examining the construct of depression in obstructive sleep apnea syndrome. *Sleep Med.* 2005; 6: 115–121.
- Glebocka A, Kossowska A, Bednarek M. Obstructive sleep apnea and the quality of life. *J. Physiol. Pharmacol.* 2006; 57 (Suppl. 4): 111–117.
- Peppard PE, Szklo-Coxe M, Hla KM, Young T. Longitudinal association of sleep-related breathing disorder and depression. *Arch. Intern. Med.* 2006; 166: 1709–1715.